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INTRODUCTION 
Obsessive-Compulsive Spectrum (OCS) disorders are characterised by persistent intrusive 
thoughts (obsessions), causing anxiety and repetitive behaviours (compulsions) [1], with 
behaviours usually directed towards assuaging anxiety [2]. Typically, in the case of obsessive 
compulsive disorder (OCD), which is the most common and best delineated of the OCS 
disorders, the individual will have good insight into the fact that their levels of worry and 
distress associated with their obsessions and compulsions are outside the normal range, and 
considerably disproportionate, but they nevertheless remain compelled to complete the 
repetitive behaviours, with undue worry about unrealistic consequences should they fail to do 
so [3]. Obsessive-compulsive disorder (OCD) affects an estimated 1.6-2.3% of the adult 
population [4, 5] and 0.25-3% in child and adolescent populations (aged 5-15) [6, 7] with a 
total cost estimate of  $10.6 billion for the annual direct and indirect costs in the US alone [8]. 
 
The broad category of OCS disorders comprises a wide range of conditions, with the 
classification systems of ICD-10 [9] and DSM-5 [1] somewhat differentially delineating 
them. Up until recently, the Diagnostic and Statistical Manual (DSM) classified OCD under 
the wider category of anxiety disorders (DSM-IV; [10], but it has now been reclassified in 
DSM-5 with its own chapter ‘Obsessive-compulsive and related disorders’ [1]. 
 
Within this chapter are included OCD; body dysmorphic disorder; hoarding disorder; 
trichotillomania (TTM; hair-pulling disorder); excoriation (skin-picking) disorder; 
substance/medication-induced obsessive-compulsive and related disorder; obsessive-
compulsive and related disorder due to another medical condition; and some other less-
specific conditions. Other psychiatric disorders which include an aspect of impulse 
dysregulation such as bulimia nervosa, bipolar disorder, schizophrenia substance misuse and 
Manuscript
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pathological gambling are sometimes likened to OCS disorders due to the highly valued and 
repetitive nature of thoughts and behaviours. The fact that pathological gambling and 
trichotillomania were classified in the same category in DSM-IV (‘Impulse-control disorders 
not elsewhere specified’) [10] further illustrates the underlying similarities between these 
disorders. Substance misuse and gambling are regarded as disorders characterised by 
impulsive/compulsive behaviours, with similar neural underpinnings to those identified in 
OCS disorders [11]. 
 
The biological bases of OCS disorders are incompletely understood. Following the finding 
that selective serotonin reuptake inhibitors (SSRI) are effective in the treatment of OCD and 
body dysmorphic disorder (BDD) in adults [12], the ‘serotonin hypothesis’ of OCS disorders 
gained popularity. Approximately 40-60% of patients respond to treatment with SSRIs  [13], 
inferring, analogous to models of depression, that more than simply a serotonin ‘deficit’ is 
important in the neurobiology of OCS disorders. The cortico-striatal-thalamic-circuit (CSTC) 
– which comprises of glutamatergic, GABAergic and dopaminergic neurons [14]  -  has been 
implicated in the basic neurobiological model of OCD [15]. The striatum is considered to be 
involved in the initiation of behavioural responses and the acquisition of new habits [16]. 
Within the CSTC circuit there are two main pathways – the direct and indirect (Figure 1). 
The direct pathway works to disinhibit the thalamus, whereas stimulation of the indirect 
pathway increases inhibition of the thalamus [17]. Normal stimulation of the direct pathway 
causes fixation on a specific behaviour in response to a particular need until this need has 
been appeased. The indirect pathway works to supress behaviours manifested driven by 
excitation of the direct pathway, allowing individuals to switch to a different behaviour [16]. 
In OCS disorders, the balance between direct and indirect pathways of the CSTC is 
considered to be disrupted, with the direct pathway having a disproportionately greater effect 
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over the indirect pathway [15]. This model posits that such imbalance may mediate OCS 
symptoms, with behaviours and cognitions that are usually held in check - such as the worries 
as following repetitive behaviours described in OCS disorders - instead being facilitated [18]. 
Evidence suggests that hyperactivity of the direct pathway may be correlated with symptom 
severity in OCD [19].   
 
The role of oxidative stress has also been implicated in OCS disorders. Oxidative stress 
occurs when there is an imbalance of cellular oxidants and antioxidants, with high levels of 
oxidants causing toxicity and neuronal death [20] and is thought to contribute to the aetiology 
of psychiatric disorders [21]. Although there is little research focusing on OCS disorders 
more generally, there are data to indicate that oxidative stress may play an important role in 
OCD [22]. Oxidative stress, caused by decreased levels of antioxidants such as glutathione 
(GSH), has been implicated in OCD, where work has shown it to be related to the severity of 
symptoms [23]. Amelioration in OCD symptom severity, as measured by reduced Yale-
Brown Obsessive Compulsive Scale (Y-BOCS) score, was found to be associated with 
decreased oxidative stress after twelve weeks of treatment with the SSRI fluoxetine 
40mg/day [22]. The physiological correlates for this are not well understood at this time: the 
general finding of altered immune states is common to many mental illnesses [20], though 
arguments persist about sensitivity, specificity, and causality. 
 
Treatment: current protocols and problematic efficacy 
In the US, practice guidelines for the treatment of OCD advocate the use of both 
psychological and pharmacological interventions [24]. Psychological treatments are generally 
considered the most efficacious strategy, typically adopting Cognitive Behavioural Therapy 
(CBT) approaches. However waiting times for such interventions can be considerable, and 
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not all individuals improve with CBT, with data showing an improvement in target symptoms 
by more than 50% in just over half of OCD patients [2]. It is common for pharmacological 
interventions to be given whilst waiting for psychological treatment, in parallel to such work, 
or, in some cases depending on issues including patient choice and acceptability, instead of 
psychological work. SSRIs have been proven to be efficacious in the treatment of adults with 
OCD [24]. In children, due to concerns about SSRIs increasing suicidal thoughts, CBT is the 
first-line treatment for paediatric OCD, although SSRIs are recommended in addition to CBT 
for moderate to severe OCD [25]. 
 
To complicate matters, different studies use different criteria to determine whether or not 
people are treatment responsive [2]. There are many different axes along which severity of 
OCS symptoms can be measured, for instance time spent engaging in OCS behaviours, 
ability to resist urges, distress and impact on daily life: in clinical trials, change is generally 
measured by measures such as the Y-BOCS [26]. Typically, patients defined as ‘treatment 
responsive’ are defined as showing  a 30-35% reduction in score, meaning that someone can 
be labelled as ‘treatment responsive’, but still be left with a number of time-consuming OCS 
symptoms which if one did not know of the previous reduction, could be classified as being 
in the mild-moderate range [3]. A systematic review comparing the efficacy of different 
treatments for TTM concluded that SSRIs were no more efficacious than placebo in reducing 
the severity of TTM symptoms [27]. Undoubtedly more efficacious pharmacological 
treatments for OCS disorders are needed to augment existing treatments. 
 
N-acetyl-cysteine: Novel pharmacotherapeutics 
N-acetyl-cysteine (NAC) is the acetyl derivative of cysteine which is quickly oxidised into 
cystine [28]. Although it has traditionally been used in the treatment of paracetamol overdose 
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and as a mucolytic agent, it has been postulated that NAC may exert a therapeutic effect on 
psychiatric and psychological disorders putatively caused – at least in part - by oxidative 
stress, such as schizophrenia and bipolar disorder; and those characterised by compulsive or 
impulsive symptoms, such as trichotillomania, onychophagia (pathological nail biting), 
gambling and substance misuse [11]. 
 
There are three potential mechanisms through which NAC might effect therapeutic change. 
Firstly, NAC is thought to decrease oxidative stress through the increased availability of 
cysteine, a rate-limiting substrate for cysteine-glutamate antiporters located on glial cells 
[28]. Cysteine-glutamate antiporters are considered key in governing the baseline levels of 
extrasynaptic glutamate [29] as well as in the feedback regulation of glutamate release [30]. 
A transient increase in levels of extrasynaptic glutamate seems to cause a subsequent 
decrease in its rate of release, through the stimulation of inhibitory metabotropic glutamate 
receptors on glutamatergic nerve terminals [31]. The increase in cystine levels after NAC 
administration thus allows alteration of the rate of exchange of glutamate and cysteine via the 
antiporters [28].  
 
Secondly, cysteine is also a rate limiting substrate in the production of the antioxidant 
molecule GSH [32]. Within the cell, toxic by-products of glutamatergic neurotransmission 
and dysfunctional dopamine metabolism cause oxidative and nitrosative stress respectively 
[28]. Through the increased availability of GSH, which scavenges both of these toxic by-
products, there is a lessening of oxidative and nitrosative stress, leading to decreased cell 
damage [28].  
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Finally, aside from influencing the glutamatergic system, NAC is also thought to modulate 
dopamine release. Recent evidence suggests glutamate regulation of dopaminergic activity in 
the ventral tegmental area of the brain [28], an area in which OCD patients have functional 
differences compared to healthy controls [33]. It has been proposed that there is increased 
dopamine neurotransmission in OCD sufferers [34]. When oxidised, dopamine forms 
hydrogen peroxide and free radicals [28] with dysregulation of dopamine signalling causing 
increased levels of neurotoxicity [35]. OCD has been associated with free radicals [36]. NAC 
relieves oxidative stress caused by neurotoxins following altered dopamine signalling, and 
lessens the reduction of dopamine transporters caused by previous high levels of dopamine 
release [37]. 
 
In the US, NAC is available in liquid, intravenous and oral forms. It is generally thought of as 
a relatively safe drug [3], with there being no prescription necessary to purchase the oral 
form. Mild side-effects such as headaches, rash and fever are thought to occur in 
approximately 1-5% of patients, while moderate side-effects such as hypertension, respiratory 
distress and increased blood pressure, occur in less than 1% of patients [38]. However, NAC 
is toxic in overdose and therefore it is of the highest importance that future studies investigate 
further its safety.  
 
Aim 
OCS disorders present considerable distress and suffering to those so afflicted and existing 
psychological and pharmacological treatments have limitations to their efficacy. Nascent data 
suggest that, as part of a putative oxidative-stress model, that OCS disorders might be 
amenable to amelioration by the anti-oxidative compound NAC. This work sets out to 
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systematically review the existing evidence on the efficacy of NAC as a treatment for OCS 
disorders.  
 
 
METHOD 
 
A systematic review of the efficacy of NAC on OCS disorders was carried out according to 
the PRISMA criteria [39]. Medline, Embase, and PsycINFO were searched via OvidSP while 
the Web of Science™ core collection was searched via Web of Science. Articles published in 
English were searched from inception until January 2014. The final search took place on the 
1st July 2014 using the term ((obsessive OR compulsive) OR (skin AND picking) OR (body 
AND dysmorph*) OR hoarding OR trichotillomania OR glutamate*) AND (acetylcysteine)). 
Search terms were derived from the definition of OCS disorders according to DSM-5 [1].  
 
Eligibility criteria: 
Eligibility criteria were as follows. 
 
Participants: Studies investigating adult and paediatric populations who manifested an OCS 
disorder as described by DSM-5 [1] were considered in the review.  
 
Interventions: Studies were included if they investigated the therapeutic effect of NAC as 
either a stand-alone or adjunctive treatment for an OCS disorder.  
 
Comparators: Where studies included a control group, intervention groups were compared 
groups taking a placebo.  
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Outcomes: Studies reporting behavioural outcome measures associated with OCS disorders, 
whether quantified by comprehensive measures e.g. Yale-Brown Obsessive Compulsive 
Scale (Y-BOCS) [26] or Clinical Global Impression (CGI) [40] or described anecdotally were 
included. 
 
Study design: Randomised control trials, retrospective case reports and case studies were 
included in the review. 
 
Report characteristics: Reports published in English were included in the review. 
 
 
RESULTS 
 
Ten studies ultimately fulfilled the inclusion criteria (see Figure 2). Initially a total of 1007 
records were identified by one of the authors (LS) after searching Medline, Embase, 
PsycINFO and Web of Science™ Core Collection. After removing duplicates, articles not in 
English and non-human studies a total of 618 records were left. The titles of these were 
screened and 59 records were identified as needing more thorough evaluation. The full texts 
of these articles were accessed and 49 were excluded, leaving ten studies to be included in 
synthesis. Of these: four were double-blind placebo-controlled trials; five were case studies; 
and one was a retrospective chart review. Three studies investigated cohorts of OCD patients; 
two investigated patients with TTM; two onychophagia; one dermatillomania; one described 
cases of TTM, dermatillomania and onychophagia; and one described cases of 
dermatillomania and TTM. All studies looked at adult populations except for two, [41, 42] 
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which investigated paediatric populations. For a full description of the studies and data 
extracted, see Table 1. Only one trial involved concurrent psychological intervention [41]. 
 
i) NAC and OCD 
 
Three studies investigated the effect of NAC on OCD using various methodologies (one 
randomised placebo-controlled study, one retrospective chart review and one case study). 
Number of participants included in each study varied from only one to 48 with a follow-up 
period of 12-13 weeks. 
 
Of the three studies investigating the effect of NAC on OCD, there was only one randomised, 
double-blind, placebo-controlled study [43]. In this 12 week study of 48 participants (mean 
age 30.93) half were randomised to the treatment group (NAC 600mg/day, doubled every 
week to a final dose of 2400mg/day), half to the placebo control group.  Patients were 
recruited from two hospitals and had a primary diagnosis of OCD. Diagnoses were made by 
an experienced psychiatrist utilising DSM-IV [44]. Patients had failed to show a treatment 
response, defined as a Y-BOCS score of 15 or less, after 12 weeks of treatment with an SSRI. 
All participants continued on stable doses of medication during the study, and by the end of 
the twelve weeks 52.6% NAC patients had a full clinical response, defined as a 35% or 
greater reduction in Y-BOCS score, compared to 15% in the control group. However the rate 
of adverse events in the NAC group was notable, with eight patients reporting 
nausea/vomiting and four reporting mild diarrhoea. As a consequence of the adverse effects 
of NAC, three participants (12.5%) discontinued the study. 
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A retrospective chart review of 6 patients (mean age 48.8) with treatment resistant OCD with 
no control group was undertaken by Van Ameringen et al. [45]. Participants, who were all on 
SSRIs, were commenced on 500mg/day of NAC, increased to a maximum of 3000mg/day 
depending on tolerability and clinical response. Only one patient was found to have a 
therapeutic response to NAC over the intervention period of 12 weeks, defined by a 35% 
reduction in Y-BOCS score and a reduction of symptom severity as measured by the CGI 
scale [40] to 2. 
 
The earliest study was a single case study documenting the symptoms of a 58 year-old female 
with childhood onset OCD, confirmed using a structured clinical interview [46]. NAC was 
administered for a total intervention period of 13-weeks alongside fluvoxamine 300mg/day. 
The initial dose was 600mg/day, but was titrated up to a total daily dose of 3000mg/day over 
the course of six weeks. There was a significant decrease in Y-BOCS score, and 
improvement in self-reported symptoms, which was maintained at a 2-month follow-up. 
 
Taken together, the results of these three studies cautiously indicate the efficacy of NAC in 
the treatment of OCD. The most methodologically robust of these studies, the randomised, 
double-blind, placebo-controlled study carried out by Ashfar et al. [43] indicates significant 
difference in Y-BOCS and Clinical Global Impression-Severity Scale (CGI-S) score between 
the treatment and control group. However, the retrospective chart review (no randomisation, 
blinding or placebo-control) indicated a poor effect of NAC in the treatment of OCD. One 
strength of these findings is that each study has used a comprehensive scale upon which to 
base their findings as opposed to subjective measures such as self-report. 
 
ii) NAC and TTM 
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Of the three studies investigating the effects of NAC on TTM, two were moderately sized 
double-blinded placebo-controlled RCTs (one conducted in an adult cohort and the other 
conducted in a paediatric cohort), and the final study was a case series.  Studies ranged from 
including three participants to 50 participants, with a follow-up of 11 weeks to 7 months. 
 
The most recent RCT was a twelve week trial [41] in a paediatric cohort (age range 8-17; 
n=39) randomised to NAC (n=20; dose titrated to a maximum of 2400mg/day over 4 weeks) 
and placebo (n=19). Participants had a primary diagnosis of TTM and were being treated 
with psychotherapy and stable medication (no addition, discontinuation or changes to dose in 
the 4 weeks prior to the trial). All subjects, regardless of intervention group, showed a 
statistically significant improvement in hair-pulling (measured by the Massachusetts General 
Hospital Hair-pulling Scale. (MGH-HPS) [47]. 
 
The other RCT [48] was conducted over 12 weeks in an adult cohort (n=50) with TTM 
randomised to NAC (n=25; dosed 1200mg/day for the first six weeks, thereafter increased to 
2400mg/day) or the control group (n=25). All patients had a primary diagnosis of TTM as 
defined by DSM-IV [44]. Patients were included in the study if they had been taking a stable 
dose of medication for three months prior to the onset of the study and had no plans to change 
the dose during the study. Participants attending psychotherapy were also included in the 
study, as long as they had been attending for at least six months before the study. Participants 
in the treatment group showed a significant improvement compared to controls on both the 
severity subscale and the resistance and control subscale of the MGH-HPS (p<0.001 for 
both). 44% of the treatment group showed a 50% or greater reduction on the MGH-HPS 
compared to 0% of the control group. There was also a significant improvement shown on the 
Psychiatric Institute Trichotillomania Scale (p=0.001; PITS) [49] in the treatment as 
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compared to the control cohort. 56% NAC patients were ‘much’ or ‘very much’ improved at 
the trial’s conclusion, as measured by the CGI scale, whereas this was the case for only 16% 
of the control group. 
 
The case series described three patients, one of whom suffered from TTM and onychophagia, 
another who suffered only from TTM and the last who suffered from dermatillomania [50]. 
Case 1 took 600mg/day NAC for 2 weeks, after which it was increased to 1200mg/day NAC, 
and at 5 weeks further increased to 1800mg/day and maintained for 4 weeks. No other 
psychotropic medication was being taken at this time. Over the intervention period, self-
reported trichotillomania and nail biting symptoms had ceased. Case 2 had an initial dose of 
600mg/day, increased to 1200mg/day after one week, and to 1800mg/day after three weeks, 
which was maintained for 4 weeks, before being increased once more to 2400mg/day for a 
duration of 7 months. Self-reported hair-pulling behaviour had completely ceased and the 
patient no longer needed to wear a wig. Case 3 started treatment with 600mg/day NAC for 
one week after which it was increased to 1200mg/day, maintained for 3 weeks, and then 
increased to 1800mg/day for 4 months. Self-reported picking behaviours completely ceased 
and only a mild urge to pick was reported. 
 
Results from studies investigating the efficacy of NAC in TTM indicate that NAC may be 
efficacious in the treatment of TTM. Of the two RCTs carried out, one indicated a significant 
improvement in hair-pulling, as measured by the MGH-HPS, in the treatment condition but 
not the placebo condition [48]. The strength of this finding comes into question when 
considering results of the second RCT. Bloch et al. [41] found statistically significant 
decreases in hair-pulling, as measured by the MGH-HPS, in both the treatment and control 
group. Results from the case study series cautiously point toward the efficacy of NAC in the 
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treatment of OCS disorders, however all improvements are self-reported with no use of 
comprehensive rating scales. 
 
iii) NAC and onychophagia 
 
Two studies looked at the effect of NAC on nail-biting, one of which was a randomised, 
double-blind, placebo-controlled trial and the other of which was a case series. Number of 
participants ranged from three to 42 with a follow up duration of 2 months to 7 months. 
 
The RCT was carried out on a paediatric cohort aged 6-18 [42], with 42 children randomised 
to either NAC (n=21; 200mg/day, increased 800mg/day over one week) or placebo (n=21). 
Participants were diagnosed according to DSM-IV criteria using the Farsi translation of the 
Kiddie Schedule for Affective Disorders and Schizophrenia [51]. The drop-out rate was high 
for both groups, leaving 14 in the NAC and 11 in the control group for final analysis. Nail-
length increased significantly more in the NAC group at a 1-month follow-up (p<0.04; 
5.21mm compared to 1.18mm in the control group); however, there was no statistically 
significant difference in nail-length at the 2-month follow-up. 
 
NAC was found to have a therapeutic effect on nail-biting in a set of case studies documented 
by [52]. All three patients described in the study were being treated with NAC for bipolar 
disorder and experienced a subsequent alleviation of nail-biting behaviour. Case 1 took 
2000mg/day NAC for 7 months, alongside lithium 900mg/day and quetiapine 300mg/day, 
with nail biting behaviour ceasing in the first two weeks. This amelioration continued for the 
entirety of the intervention period. Case 2 also took 2000mg/day NAC, this time for six 
months: after four months self-reported nail biting behaviour had ceased and was maintained 
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for the rest of the intervention period. Other medications being taken during the intervention 
period were 15mg/day mirtazapine, fish oil, zinc, magnesium, vitamin B6 and valerian. Case 
3 took an unreported dose of NAC for 28 weeks, over which time there were self-reports of a 
reduction of nail-biting behaviour. No concurrent use of other medication was reported. 
Although this series was identified because participants were suffering from bipolar disorder, 
this study was not excluded from the review because pathological nail-biting is presently 
identified in DSM-5 under ‘other specified obsessive-compulsive and related disorders’ [1]. 
 
Together, these findings indicate that NAC may be an effective treatment for onychophagia, 
however strength of results is limited by the small sample sizes in both studies. The larger of 
the two studies randomised a total of 42 participants to treatment and placebo groups, but 
only reported results for 25 participants after a large number of participants dropped out of 
the study [42]. The strength of these findings of efficacy of NAC for onychophagia is also 
marred by the results indicating a statistically significant difference in nail-length between the 
treatment and control group only at the 1-month follow-up, with there being no statistical 
significant difference at the 2-month follow-up. The case series indicated only the cessation 
of self-reported nail-biting behaviour with no objective measurements available.  
 
iv) NAC and dermatillomania 
 
Two studies were found investigating the effect of NAC on dermatillomania, a case series 
and a case study. Number of participants ranged from one to three. Treatment and follow-up 
duration was unspecified in three of the four participants identified by these studies, but one 
follow-up duration is mentioned to be 10 months with a different participant shown to have a 
reduction in skin-picking behaviour for 1 year. 
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The case series of the treatment of NAC in skin-picking disorder described outcomes in three 
individuals [53]. Case 1 was diagnosed with a depressive episode, TTM and skin-picking. 
1200mg/day NAC was taken over an unstated treatment period, alongside 75mg/day 
venlafaxine. During this period, self-reported skin-picking behaviour resolved and hair-
pulling behaviour was described as improving partially. The patient then discontinued all 
medication resulting in a worsening of all symptoms. NAC was reinstated at a dose of 
1800mg/day, as was venlafaxine at 75mg/day, after which there was again complete recovery 
from skin-picking behaviours and an improvement in hair-pulling behaviours. Case 2 
developed skin-picking after having taken lithium 600mg/day and quetiapine 50mg/day for 1 
month, though the reasons for being on such medications were not clearly stated. 
1200mg/day NAC was introduced taken for 10 months, over which period self-reported skin-
picking behaviour reduced. NAC was then discontinued and skin-picking behaviour was 
reinstated. After re-introducing NAC, skin-picking behaviour subsequently improved greatly. 
Case 3 took 1200mg/day NAC for an unstated period alongside fluoxetine 20mg/day as 
treatment for a moderate depressive episode, severe skin picking, pathological jealousy and 
an internet addiction. There was a substantial improvement in self-reported skin-picking 
behaviour. 
 
A case study of a 24 year-old female treated with NAC for skin-picking disorder [54] was 
also identified. The participant also engaged in eight sessions of habit reversal therapy over 
the first weeks of the intervention period. Although neither the length of the intervention 
period nor the dose of NAC is stated, self-reports of skin-picking behaviour showed a 
reduced length of time spent engaging in the compulsive behaviour every day. This reduction 
in skin-picking behaviour was maintained for 1 year. 
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Results of studies investigating the efficacy of NAC in the treatment of dermatillomania 
indicate that NAC may have ameliorative effects on the presence of skin-picking behaviours. 
However, the strength of these studies is very weak, with there being no RCTs in the field. 
Results for the participants that are described here should be interpreted with caution, due to 
their small number and incomplete information on study duration and NAC treatment. 
 
 
DISCUSSION 
 
Despite the general dearth of information on the subject, our findings suggest there may be a 
potential efficacy of NAC in the treatment of OCS disorders as a stand-alone or adjuvant 
therapy, albeit much data are nascent and in methodologically less rigorous forms such as 
case series. In adult cohorts, randomised, placebo-controlled trials indicated the efficacy of 
NAC in combination with already stable psychotropic medication for the treatment of OCD 
[43] and TTM [48]. Case studies also indicated the efficacy of NAC as a stand-alone or 
adjunct treatment for OCD [46], TTM, excoriation and nail-biting disorder [50, 52-54]. 
However, a retrospective chart review indicated that NAC was not efficacious in the 
treatment of OCD [45]. Where comprehensive testing measures, such as the Y-BOCS [26], 
were used, some studies indicated a statistically significant improvement in measures of OCS 
disorders [43, 46, 48], whereas case studies described the amelioration of symptoms 
anecdotally [50, 52-54]. Both studies investigating paediatric cohorts were randomised, 
placebo-controlled trials which investigated the efficacy of NAC in combination with other 
stable psychotropic medication. NAC was found to be efficacious in the treatment of nail-
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biting disorder after 1 months of treatment, although this therapeutic benefit was no longer 
visible after two months of treatment [42], and not found to be efficacious in TTM [41]. 
Adverse side effects were only reported in four studies [41-43, 50]. These ranged in severity, 
from mild flatulence [50] and nausea [43], to development of a full-body rash [41]. On the 
whole, drop-out rates were also low. Reasons for dropping out were linked to inability to 
comply with study demands [48] as well as adverse effects [41-43].  
 
Previously, much neurobiological focus has been directed towards the serotoninergic system, 
in no small part due to the therapeutic effect SSRIs can have on OCS behaviours. 
Medications targeting the glutamatergic system are in the early stages of research for their 
use in psychiatric disorders, such as OCS disorders. 
 
High levels of oxidative stress, caused by decreased levels of glutathione has been shown to 
be correlated to the severity of symptoms of OCD [23]. NAC decreases oxidative stress by 
increasing the availability of cysteine, a rate-limiting substrate of cysteine-glutamate 
antiporters [28]. Cysteine-glutamate antiporters work to regulate extrasynaptic glutamate 
levels and are implicated in the feedback of glutamate release [11]. Increased rates of 
cysteine made available through the administration of NAC helps regulate extrasynaptic 
levels of glutamate. Glutamate regulation has recently been shown to affect dopamine 
transmission [28], which is also abnormal in OCD [33, 34]. 
 
The availability of cysteine is also a rate-limiting factor for the production of GSH [32]. The 
increased availability of cysteine following the administration of NAC therefore allows for 
the increased production of GSH. As GSH scavenges toxic by-products of oxidative and 
nitrosative stress, an increase in will result in decreased cell damage [28]. 
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NAC has been shown to have clinical utility outside of OCS disorders, in the treatment of 
disorders of addiction, in which similar areas of the brain are implicated as those in OCS 
disorders [55, 56]. Seeing as drug addiction involves compulsive drug use [57] analogous to 
the compulsive behaviours seen in OCS disorders, this is perhaps unsurprising. Research into 
the treatment of drug addiction with NAC has shown promising results in reduction of drug 
use, cravings, withdrawal symptoms and relapse in cocaine [58, 59], marijuana [60] and 
nicotine addiction [61, 62]. NAC has also been shown to alleviate pathological gambling 
behaviour [63]. It has been hypothesised that NAC may be an effective treatment of anxiety 
disorders [11, 64], with which OCD was previously classified in DSM-IV-TR [10]. 
 
The results of this systematic review point cautiously towards the potential efficacy of NAC 
for the treatment of OCS disorders. Strengths of systematic reviews include the ability to 
collate all available evidence in order to clarify otherwise contradictory findings. In order to 
do this successfully, one must be mindful of the nature of the studies reviewed when 
interpreting results. Randomised, placebo-controlled trials were in the minority of the studies 
reviews, and even then, only two out of four studies demonstrated statistically significant 
differences between NAC and placebo treatment groups on comprehensive testing measures 
of the symptoms of OCS disorders [43, 48]. Of the remaining two studies, one showed 
statistically significant differences between the NAC and placebo treatment groups on nail-
biting behaviour only at one-month follow-up, but these effects were no longer present at the 
two-month follow-up [42].  Bloch et al. [41] found no statistically significant difference 
between NAC and placebo treatment groups on a comprehensive measure of hair-pulling in 
paediatric TTM. A retrospective case review did not find any therapeutic effect of NAC on 
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OCD as measured by a comprehensive measure of OCD symptoms [45]. Case studies all 
indicated a therapeutic effect of NAC on OCS in adult cohorts. 
 
One issue these studies face is the controversy in the diagnosis of OCS disorders. With the 
introduction of OCS disorders as a chapter in itself in DSM-5 [1] and the reclassification of 
some OCS disorders, there will likely be a period of confusion in the diagnosis of OCS 
disorders. This systematic review is further limited by language restrictions, with only 
English articles being reviewed. Due to the heterogeneity of the studies identified, it was not 
possible to conduct a meta-analysis to quantifiably determine the therapeutic effect of NAC 
on OCS disorders. 
 
The number of randomised, placebo-controlled trials investigating the therapeutic effect of 
NAC on OCS disorders is very small, with further trials needed before a conclusive statement 
can be drawn regarding the efficacy of NAC in the treatment of such disorders. In an attempt 
to further understanding, three clinical trials are currently recruiting participants; two 
investigating OCD, one investigating a paediatric population (ClinicalTrials.gov: 
NCT01172275) and the other an adult population (ClinicalTrials.gov: NCT01555970), and 
one study investigating pathologic skin-picking (ClinicalTrials.gov: NCT01063348). This is a 
difficult area of research, with substantial difficulties when it comes to recruiting participants, 
resulting in the unfortunate termination of one recent clinical trial investigating NAC as a 
treatment for OCD in those for whom SRIs did not have a therapeutic effect 
(ClinicalTrials.gov: NCT00539513). 
 
The clinical implications of this review are far reaching. Only 40-60% patients show a 
response to treatment with SSRIs [13], which are currently the first-line treatment for OCS 
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disorders such as OCD, BDD, TTM and excoriation disorder [12]. This leaves a high 
proportion of patients showing a less-than-optimal treatment-response to SSRIs, highlighting 
the importance of verifying the efficacy of other possible treatments for OCS disorders in 
order to optimise treatment. In those for whom SRIs do provide some amelioration, but not 
total cessation of symptoms, results indicate that NAC could be a useful adjuvant therapy. 
 
As well as precipitating the amelioration of OCS symptoms, NAC seems to be well-tolerated, 
with few, mild adverse effects being caused. In addition to these features, NAC is also 
inexpensive and does not require a prescription [65], making it a very enticing option for the 
future treatment of OCS disorders. Placebo-controlled studies are lacking and more research 
is required to determine the guideline therapeutic dose, for both adults and children. 
Nevertheless, NAC has been shown to ameliorate behavioural compulsions manifested in 
OCS disorders. With clinical trials underway to further understanding, one can be cautiously 
optimistic about the promise of NAC as a treatment for OCS disorders. 
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Figure 1. Figure showing the direct and indirect pathways within the CSTC. 
 
CSTC = cortico-striatal-thalamic-circuit; GPe = globus pallidus externa; GPi = globus 
pallidus interna; STN = sub-thalamic nucleus; SNr = substantia nigra pars reticulata 
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Figure 2. Flow diagram showing study selection. 
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Figure 1
Table 1. OCS disorders as classified by DSM-5 and ICD-10. 
 
DSM-5  
Obsessive-
compulsive 
disorder 
ICD-10 
Habit and impulse 
disorders 
 
Somatoform 
disorders 
Obsessive-Compulsive 
Disorder 
Obsessive-
compulsive disorder 
  
 Predominantly 
obsessional 
thoughts or 
ruminations 
  
 Predominantly 
compulsive acts 
[obsessional rituals] 
  
 Mixed obsessional 
thoughts and acts 
  
Body Dysmorphic 
Disorder 
  Hypochondriacal 
disorder (includes 
body dysmorphic 
disorder) 
Hoarding Disorder*    
Trichotillomania  Trichotillomania  
Excoriation Disorder*    
Substance/Medication-
Induced Obsessive-
Compulsive and 
Related Disorder* 
   
Obsessive-Compulsive 
and Related Disorder 
Due to Another 
Medical Condition* 
   
Other Specified 
Obsessive-Compulsive 
and Related Disorder 
Other obsessive-
compulsive 
disorders 
Other habit and 
impulse disorders 
 
Unspecified Obsessive-
Compulsive and 
Related Disorder 
Obsessive-
compulsive 
disorder, 
unspecified 
Habit and impulse 
disorder, unspecified 
 
* Those that are only classified in DSM-5. 
 
 
 
Table 1 - Updated
Table 2. The epidemiology of OCS disorders, licensed treatments and their efficacy. 
Disorder Prevalence Typical age of 
onset, gender 
distribution (if 
available) 
Licensed 
treatment(s) 
 
NICE 
Guidelines 
Outcome data (if 
available) 
OCD 
 
1.6-2.3% 
adult 
population 
Mean age of 
onset = 22-36. 
Males seem to 
develop OCD 
slightly earlier 
than females. 
 
Approximately 
1:1 female:male. 
 
First line – 
fluoxetine
b
, 
fluvoxamine, 
paroxetine, 
sertraline
b
, 
citalopram.  
Second line - 
clomipramine  
 
Measurement: 
difference in Y-
BOCS scores 
pre/post-test. 
Sertraline more 
efficacious than 
clomipramine; 
fluvoxamine as 
efficacious as 
clomipramine. 
Fluoxetine less 
efficacious than 
clomipramine. 
 
SSRIs and 
clomipramine show 
greater benefit vs 
placebo. Most 
improvement with 
clomipramine, then 
fluoxetine, 
fluvoxamine, 
sertraline. 
Body dysmorphic 
disorder
a
 
 
 
0.5-1.1% 
adult 
population; 
2.2% 
adolescent 
population 
Usually begins 
in early 
adolescence. 
 
Approximately 
1:1 female:male. 
First line – 
fluoxetine. 
Second line  - 
different SSRI 
(fluvoxamine, 
paroxetine, 
sertraline, 
citalopram) or 
clomipramine 
SRIs often 
efficacious. 
Psychological 
therapies were more 
effective than 
pharmacotherapy. 
Fluoxetine 
significantly more 
effective than 
placebo 
Hoarding 
disorder 
(included in OCD 
+ BDD according 
to  NICE 
guidelines) 
2-5% adult 
population  
More 
prevalent in 
older than 
younger 
adults and 
children 
Hoarding 
symptoms begin 
at average age 
of 12-13; 
interference 
with everyday 
functioning in 
mid-30s. 
 
Mixed findings; 
some studies 
Treatment 
according to 
guidelines for 
OCD; hoarding 
symptoms 
rarely treated 
on their own 
Relatively worse 
response to SSRIs 
compared with other 
OCD symptoms 
Hoarding symptoms 
reported to improve 
as much as other 
symptoms of OCD 
after paroxetine 
Table 2 - Updated
indicate higher 
prevalence in 
females, others 
indicate higher 
prevalence in 
males  
Trichotillomania 
(included in OCD 
+ BDD according 
to NICE 
guidelines) 
0.6-1% 
adolescents 
and young 
adult 
population  
 
7 times 
more 
prevalent in 
adults than 
in children 
Age of onset 10-
13. Illness 
duration 
approximately 
16-17 years. 
 
More common 
in females at all 
ages. 
 
Treatment 
according to 
guidelines for 
OCD 
Significant treatment 
effect favouring 
clomipramine vs 
control conditions. 
No difference 
between SSRI 
pharmacotherapy 
and control 
conditions  
SSRIs include 
fluoxetine, 
sertraline; TCAs 
include 
clomipramine, 
desipramine. 
Excoriation 
disorder
a
 
1.4-5.4 in 
general 
adult 
population  
Approximately 
8:1 Female:male 
ratio, 8:1 (NB - 
may reflect 
differences in 
seeking 
treatment) 
Treatment 
according to 
guidelines for 
OCD 
SSRIs (fluoxetine, 
fluvoxamine, 
sertraline, 
paroxetine), 
doxepin, 
clomipramine, 
naltrexone, 
pimozide, 
olanzapine may be 
effective in reducing 
skin-picking  
a
 Those that differ between DSM-5 and ICD-10 
b
 Treatments licensed for children aged 8-18 in the UK 
 
 
 
Table 3. Articles identified in systematic review; methodologies and findings. 
Table 3 - Updated
Study OCS 
disord
er 
Method 
of 
diagnosis 
Comorbi
dities 
Participa
nts 
(number, 
mean 
age) 
Study 
design 
Dose 
(mg) and 
duration 
Other 
concurrent 
pharmacol
ogical 
treatment 
Other 
concurren
t 
psychologi
cal 
treatment 
Outco
me 
measu
re 
Findings Dropout 
rate, 
adverse 
effects 
Afshar 
et al. 
(2012) 
[41] 
OCD Diagnosis 
made by 
experienc
ed 
psychiatri
st based 
on DSM-
IV 
Not 
reported. 
Comorbid
ities 
diagnosed 
by 
experienc
ed 
psychiatri
st using 
DSM-IV 
N=48. 
Mean 
age=30.93 
Randomi
sed, 
double-
blind, 
placebo-
controlle
d trial 
Initial 
dose of 
600mg/d. 
Doubled 
weekly to 
maximu
m dose of 
2400mg/
d 
(dependin
g on 
individua
l 
tolerance 
and CGI-
I score). 
12 week 
interventi
on 
period. 
SRI 
treatment 
continued 
throughout 
study at 
same dose 
as in pre-
intervention 
phase 
None. 
Patients 
undergoing 
psychother
apy or 
behavioura
l therapy 
were 
excluded 
from the 
study. 
Y-
BOCS, 
CGI-I 
scale, 
CGI-S 
scale 
Significa
nt 
differenc
e in Y-
BOCS 
score, 
CGI-S 
scale 
score 
between 
groups. 
No 
significa
nt 
differenc
e in 
CGI-I 
score 
between 
groups. 
Mild-
moderate 
nausea/vom
iting, n=8. 
Mild 
diarrhoea, 
n=4. 
 
3/24 
participants 
in NAC 
condition 
dropped out 
due to 
adverse 
effects 
Van 
Amerin
gen et 
al. 
(2013) 
[43] 
OCD Standardi
sed initial 
assessme
nt using 
Structure
d Clinical 
Interview 
for DSM-
IV 
(SCID). 
5/6 had 
comorbid 
conditions
.
a
 
N=6. 
Mean 
age=48.8 
years. 
Retrospe
ctive 
chart 
review 
Initial 
dose of 
500mg/d, 
increased 
to 
maximu
m dose of 
3000mg/
d, 
dependin
Doses of 
concurrent 
OCD 
medication 
had been 
stable for at 
least 8 
weeks
)
. 
Not 
reported 
Y-
BOCS, 
CGI 
scale. 
Only 1/6 
patients 
responde
d to 
NAC. 
Two 
patients 
reported 
worsenin
g of 
5/6 patients 
continued 
treatment 
for 12-
week 
period. No 
adverse 
effects. 
Clinical 
interview 
with a 
psychiatri
st to 
confirm 
diagnosis 
g on 
clinical 
response 
and 
tolerabilit
y. 
Interventi
on period 
of up to 
12 weeks. 
symptom
s. 
LaFleur 
et al. 
(2006) 
[44] 
OCD Diagnosis 
confirme
d through 
Structure
d Clinical 
Interview
. 
History of 
recurrent 
major 
depression
; in 
remission 
for over 
12 years. 
N=1. 58 
years old. 
Case 
study 
Initial 
dose of 
600mg/d. 
Titrated 
to daily 
dose of 
3000mg/
d over 
period of 
6 weeks 
and 
maintaine
d for 7 
weeks.  
300mg/d 
fluvoxamin
e 
No formal 
or manual-
driven 
cognitive 
behavioura
l treatment 
plan 
Y-
BOCS. 
Self-
reporti
ng of 
intrusi
ve 
though
ts. 
Decrease 
in Y-
BOCS 
score. 
Less 
disturbed 
by 
intrusive 
thoughts. 
None 
reported 
Bloch et 
al. 
(2013) 
[39] 
TTM Participa
nts had a 
primary 
diagnosis 
of TTM.  
Not 
reported.  
N=39. 
Mean age; 
NAC=14.
0, 
placebo=1
3.1 
Randomi
sed, 
double-
blind, 
placebo-
controlle
d, add-on 
trial 
Initial 
dose of 
600mg/d. 
After one 
week 
increased 
to 
1200mg/
All children 
on stable 
medication. 
Exact doses 
not 
reported. 
Participant
s required 
to be on 
stable 
psychother
apy (over 3 
months).  
MGH-
HPS 
25% 
treatmen
t 
responde
rs (vs 
21% 
placebo). 
 
1 case of 
full-body 
rash which 
dissipated 
after NAC 
discontinue
d. 
Reported 
d. 12 
weeks 
interventi
on 
period. 
No 
benefit if 
NAC as 
add-on 
for 
pediatric 
TTM. 
missing a 
significant 
number of 
doses, 
NAC = 2; 
placebo = 
1. 
 
Grant 
et al. 
(2009) 
[46] 
TTM Patients 
met 
DSM-IV 
criteria 
for TTM, 
using 
physician
-
administe
red TTM 
Diagnosti
c 
Interview 
28% 
reported 
symptoms 
consistent 
with 
major 
depressive 
disorder, 
28% had 
an anxiety 
disorder, 
36% had 
another 
impulse 
control 
disorder, 
2% had an 
eating 
disorder 
N=50. 
Mean age; 
NAC=35.
7, 
placebo=3
2.7 
Randomi
sed, 
double-
blind, 
placebo-
controlle
d trial 
1200mg/
d for 6 
weeks, 
raised to 
2400mg 
for last 6 
weeks 
unless 
clinical 
improve
ment. 
56% 
patients 
taking 
psychotropi
c 
medication.  
NAC group 
– 48%, 
placebo 
group – 
64%. 
Medication 
required to 
be stable for 
3 months  
8% 
patients 
attending 
individual/
group 
psychother
apy. All 
had been 
with the 
same 
therapist 
for at least 
1 year 
(weekly 
attendance)
. 
MGH-
HPS. 
PITS, 
CGI 
scale. 
Significa
nt 
improve
ment in 
MGH-
HPS, 
PITS 
and CGI 
scores in 
NAC 
group.  
6 dropouts 
(88% 
completion
). 5 unable 
to comply 
with study 
schedule, 1 
unrelated 
health 
concerns. 
No adverse 
effects in 
NAC 
group. 
 
Odlaug 
& 
Grant 
(2007) 
[48] 
Case 
1=TT
M and 
nail-
biting. 
Subjects 
underwen
t 
structured 
clinical 
Case 1, 
history of 
ADHD, 
diagnosed 
at age 5. 
N=3. Case 
1 age=28 
Case 2 
age=40. 
Case 3 
Case 
study 
Case 1= 
final dose 
1800mg. 
Total 
interventi
Case 1 = no 
other 
psychotropi
c 
medications
Case 1 = 
none 
reported. 
Case 2 = 
none 
Self-
reporti
ng of 
skin-
pickin
Case 1 = 
improve
ment of 
skin-
picking 
Case 1 = 
Mild 
flatulence 
during first 
2 weeks. 
Case 
2=TT
M. 
Case 
3=skin
-
pickin
g. 
NB – 
5 
patient
s 
enrolle
d in 
study, 
only 
those 
who 
respon
ded 
were 
presen
ted. 
interview
s. 
Case 2, 
not 
reported. 
Case 3, no 
comorbidi
ties, but 
history 
consistent 
with 
bulimia 
nervosa. 
age=52. on period 
of 
approxim
ately 7 
months. 
Case 2= 
final dose 
2400mg/
d. Total 
interventi
on period 
of 
approxim
ately 8 
months. 
Case 3= 
final dose 
1800mg/
d. Total 
interventi
on period 
of 
approxim
ately 6 
months. 
.  
Case 2 = 
none 
reported. 
Case 3= 
none 
reported. 
concurrent 
with NAC 
treatment. 
Case 3 = 
none 
concurrent 
with NAC 
treatment. 
g and 
hair-
pulling 
behavi
our. 
and hair-
pulling 
behaviou
r. 
Case 2 = 
complete 
abstinen
ce from 
and 
cessation 
of urges 
to pull 
hair. 
Case 3 = 
complete 
absence 
of 
picking 
behaviou
r, with 
occasion
al urges. 
Case 2 = 
none 
experience
d. 
Case 3= 
none 
reported. 
Ghaniza
deh et 
al. 
(2013) 
[40] 
Nail-
biting 
Diagnosis 
made 
according 
to DSM-
IV 
diagnosti
c criteria 
. NAC 
group, 
n=10. 
Placebo 
group, 
n=9
 b
. 
N=42. 
Mean age 
NAC=9.2
8, 
placebo=1
0.76. 
Randomi
sed, 
double-
blind, 
placebo-
controlle
d trial 
Initial 
dose of 
200mg/d. 
Increased 
to 
800mg/d 
over 
NAC group 
– 9/14 
children 
taking other 
medication 
b
. Placebo 
group – 
Participant
s were 
excluded if 
they were 
participatin
g in any 
psychologi
Increas
ed nail 
length. 
Significa
nt 
increase 
only in 
NAC 
group at 
1 month. 
NAC 
group, 
dropped out 
due to 
adverse 
effects, 
n=2. 
using the 
Farsi 
Translati
on of the 
Kiddie 
Schedule 
for 
Affective 
Disorders 
and 
Schizoph
renia and 
physical 
examinati
on. 
course of 
a week 
Total 
interventi
on period 
of 2 
months. 
11/11 
b
. cal therapy 
for nail-
biting. 
(No 
differenc
e at 2 
months) 
Berk et 
al. 
(2009) 
[50] 
Nail-
biting 
No 
formal 
diagnosis 
of nail-
biting 
reported 
All 
diagnosed 
with 
bipolar 
disorder. 
Case 1 = 
other 
diagnosed 
comorbidi
ties. Cases 
2 and 3 = 
symptoms 
of other 
psycholog
ical 
disorders
c
 
N=3. Case 
1 age=46. 
Case 2 
age=44. 
Case 3 
age=46. 
Case 
study 
Case 
1=2000m
g/d, 7 
months. 
Case 
2=2000m
g/d, 4 
months. 
Case 
3=2000m
g/d, 7 
months. 
Case 
1=900mg 
lithium, 
300mg 
quetiapine. 
Case 
2=15mg 
mirtazapine. 
None 
reported 
Self-
reports 
of nail-
biting 
behavi
our. 
Stopping 
of nail-
biting. 
None 
reported 
Grant 
et al. 
(2012) 
[52] 
Skin-
pickin
g 
disord
er 
Meets the 
proposed 
diagnosis 
for skin-
picking 
disorder 
None 
reported 
N=1. 24 
years old. 
Case 
study 
Dose not 
reported. 
Duration 
of 1 year. 
None 
reported 
8 sessions 
of habit 
reversal 
therapy 
over 
several 
weeks 
Self-
report 
of 
skin-
pickin
g 
behavi
our 
Skin 
picking 
behaviou
r 
reduced 
from 2-3 
hours to 
5-10  
minutes 
daily 
None 
reported 
Silva-
Netto  et 
al. 
(2014) 
[51] 
Case 1 
= skin-
pickin
g 
disord
er and 
TTM 
Case 2 
= skin 
pickin
g 
disord
er 
Case 3 
= skin 
pickin
g 
disord
er 
Not 
reported 
Case 1 = 
depressive 
episode, 
TTM. 
Case 2 = 
symptoms 
of mania. 
Case 3 = 
moderate 
depressive 
episode, 
pathologic
al 
jealousy, 
internet 
addiction. 
N=3. Case 
1 age = 
45. 
Case 2 
=40. 
Case 3 = 
31. 
Case 
study 
 
 
 
 
 
 
 
Case 1 = 
final dose 
of 
1800mg/
d. Exact 
durations 
not 
reported. 
Case 2 = 
final dose 
of 
1200mg/
d.  Exact 
durations 
not 
reported. 
Case 3 = 
1200mg/
d.  Exact 
durations 
not 
reported. 
Case 1 = 
75mg/d 
venlafaxine. 
Discontinue
d then 
reinstated at 
same dose. 
Case 2 = 
600mg/d 
lithium, 
50mg/d 
quetiapine. 
Case 3 = 
20mg/d 
fluoxetine 
Case 1 = 
none 
reporter. 
Case 2 = 
none 
reporter. 
Case 3 = 
later 
referred 
elsewhere 
for 
psychother
apy. 
Self-
reports 
of 
TTM 
and 
skin 
pickin
g 
behavi
our. 
Case 1 – 
TTM 
improve
d 
partially, 
skin 
picking 
resolved 
complete
ly. 
Case 2 – 
cessation 
of skin 
picking. 
Case 3 – 
substanti
al 
improve
ment in 
skin 
picking 
None 
reported 
 Abbreviations: NAC = n-acetylcysteine. SRI = serotonin reuptake inhibitor.  OCD = obsessive-compulsive disorder. TTM = trichotillomania. 
ADHD = Attention Deficit Hyperactivity Disorder. Y-BOCS = Yale–Brown Obsessive Compulsive Scale. CGI = Clinical Global Impression; 
CGI-I = Clinical Global Impression –Improvement; CGI-S = Clinical Global Impression –Severity. MGH-HPS = Massachusetts General 
Hospital Hair-pulling Scale. PITS = Psychiatric Institute Trichotillomania Scale. Mg/d = milligrams per day.  
 
a, b, c
= See full-text article for details. 
 
Table 4. Methodology and quality of articles included in review 
 
Table 4 - Updated
Study OCS 
disorde
r 
Number of 
participan
ts 
Study 
design 
Blinding Outcome 
measure 
Duratio
n of 
follow-
up 
Confounders Quality 
of study 
(as 
defined 
by the 
GRADE 
approac
h [53]) 
Comments 
Afshar et 
al. (2012) 
[41] 
OCD N=48 Randomise
d, double-
blind, 
placebo-
controlled 
trial 
Investigators 
blinded to the 
drugs used. 
Researchers 
involved in 
allocation to 
treatment/place
bo group had 
no role in 
treatment or 
collection of 
data 
Y-
BOCS, 
CGI-I 
scale, 
CGI-S 
scale 
12 
weeks. 
Patients 
were 
assessed 
at 4 
weeks 
and 12 
weeks. 
No systematic 
way of 
increasing dose 
of NAC to 
maximum. No 
report of 
individual final 
dose of 
participants. 
Comorbidities. 
Other 
pharmacologica
l treatments 
Moderat
e 
Larger sample size, 
more rigorous 
methodology and 
objective rating 
scale. Blinding of 
the sample not great. 
No report of inter-
rater reliability.  
Van 
Ameringe
n et al. 
(2013) [43] 
OCD N=6 Retrospecti
ve chart 
review 
No blinding Y-
BOCS, 
CGI 
scale. 
12 
weeks 
No systematic 
administration 
of NAC across 
patients. All 
patients were 
taking other 
psychotropic 
mediation. 5/6 
patients had a 
comorbid 
disorder. Not 
Low Small sample size, 
no 
randomisation/place
bo-control/blinding 
(due to nature of 
study), objective 
rating scale 
reported 
whether 
patients were 
undergoing 
concurrent 
psychological 
therapy. 
LaFleur et 
al. (2006) 
[44] 
OCD N=1 Case study No blinding Y-
BOCS. 
Self-
reporting 
of 
intrusive 
thoughts. 
2 
months 
Taking 
fluvoxamine, 
History of 
major 
depressive 
disorder.  No 
objective 
measure of 
improvement of 
symptoms. 
Very 
low 
Very small sample 
size, no 
randomisation/place
bo-control/blinding 
(due to nature of 
study), objective 
rating scale 
Bloch et 
al. (2013) 
[39] 
TTM N=39 Randomise
d, double-
blind, 
placebo-
controlled, 
add-on trial 
Subjects, 
parents, 
investigators, 
those 
performing 
assessments 
were blinded 
MGH-
HPS 
12 
weeks 
For inclusion, 
participants 
required to be 
on stable 
pharmacotherap
y and stable 
psychotherapy 
(3 months prior 
to study). Exact 
details of 
patients’ 
pharmacotherap
y and 
psychotherapy 
not reported. 
Moderat
e 
Larger sample size, 
more rigorous 
methodology and 
objective rating 
scale 
Grant et 
al. (2009) 
[46] 
TTM N=50 Randomise
d, double-
blind, 
placebo-
controlled 
trial 
Double 
blinding 
MGH-
HPS. 
PITS, 
CGI 
scale. 
12 
weeks 
56% patients 
taking 
concurrent 
psychotropic 
medication; 8% 
patients had 
concurrent 
psychotherapy. 
60% patients 
had at least one 
clinically 
important 
comorbidity. 
72% of patients 
in the treatment 
group received 
a dose increase 
after 6 weeks of 
the study 
duration (vs 
88% placebo 
group). 
Moderat
e 
Larger sample size, 
more rigorous 
methodology and 
objective rating 
scale 
Odlaug & 
Grant 
(2007) [48] 
Case 
1=TTM 
and 
nail-
biting. 
Case 
2=TTM
. 
Case 
3=skin-
N=3 Case study No blinding Self-
reporting 
of skin-
picking 
and hair-
pulling 
behaviou
r. 
Case 1 – 
4 
months. 
Case 2 – 
5 
months. 
Case 3 – 
4 
months. 
Patients had 
comorbidities. 
No systematic 
administration 
of NAC across 
patients.  No 
objective 
measure of 
improvement of 
symptoms. 
Very 
low 
Small sample size, 
no 
randomisation/place
bo-control/blinding 
(due to nature of 
study), subjective 
rating scale 
picking 
disorde
r 
Ghanizade
h et al. 
(2013) [40] 
Nail-
biting 
N=42 Randomise
d, double-
blind, 
placebo-
controlled 
trial 
Researcher who 
measured nail 
length and 
patients was 
blind to group 
allocation 
Increased 
nail 
length. 
1 month Patients had 
comorbidities
a
. 
Patients taking 
concurrent 
psychotropic 
medication.  No 
report of 
individual final 
dose of 
participants. 
High 
withdrawal rate 
from study.  
Moderat
e 
Larger sample size, 
more rigorous 
methodology and 
objective rating 
scale 
Berk et al. 
(2009) [50] 
Nail-
biting 
N=3 Case study No blinding Self-
reports of 
nail-
biting 
behaviour
. 
Case 1 – 
7 
months. 
Case 2 – 
2 
months. 
Case 3 – 
28 
weeks 
Patients had 
comorbidities 
and were taking 
concurrent 
psychotropic 
medication. No 
systematic 
administration 
of NAC across 
patients.  No 
objective 
measure of 
improvement of 
symptoms. 
Very 
low 
Small sample size, 
no 
randomisation/place
bo-control/blinding 
(due to nature of 
study), subjective 
rating scale 
Abbreviations: NAC = n-acetylcysteine. OCD = obsessive-compulsive disorder. TTM = trichotillomania. Y-BOCS = Yale–Brown Obsessive 
Compulsive Scale. CGI = Clinical Global Impression; CGI-I = Clinical Global Impression –Improvement; CGI-S = Clinical Global Impression –
Severity. MGH-HPS = Massachusetts General Hospital Hair-pulling Scale. PITS = Psychiatric Institute Trichotillomania Scale. 
 
Grant et 
al. (2012) 
[52] 
Skin-
picking 
disorde
r 
N=1 Case study No blinding Self-
report of 
skin-
picking 
behaviour 
1 year No report of 
any 
comorbidities 
or other therapy 
(pharmacothera
py or 
psychotherapy) 
reported. No 
objective 
measure of 
improvement of 
symptoms. 
Very 
low 
Very small sample 
size, no 
randomisation/place
bo-control/blinding 
(due to nature of 
study), subjective  
rating scale 
Silva-
Netto et al. 
(2014) [51] 
Case 1 
= skin- 
picking 
disorde
r and 
TTM 
Case 2 
= skin- 
picking 
disorde
r 
Case 3 
= skin- 
picking 
disorde
r 
N=3 Case study  No blinding Self-
reports of 
skin-
picking 
and hair-
pulling 
behaviour 
Case 1 – 
not 
reporter. 
Case 2 – 
over 10 
months, 
not 
specifie
d. Case 
3 – not 
reported
. 
Patients had 
comorbidities 
and were taking 
other 
psychotropic 
medication. No 
mention of 
psychotherapy. 
No systematic 
administration 
of NAC across 
patients.  No 
objective 
measure of 
improvement of 
symptoms. 
Very 
low 
Small sample size, 
no 
randomisation/place
bo-control/blinding 
(due to nature of 
study), subjective  
rating scale 
a
= See full-text article for details of comorbidities. 
 
